Mrázová M, Svandová E, Smelhausová M, Sestáková Z, Benes C
Centre of Epidemiology and Microbiology, NRL for mumps, measles and rubella, National Institute of Public Health, Prague, Czech Republic.
Cent Eur J Public Health. 2003 Dec;11 Suppl:S36-41.
In total, 3,013 sera from a representative population sample of the Czech Republic aged from 1 to 64 years were tested according to the requirements of the ESEN 2 project using a commercial kit Measles IgG (II) EIA manufactured by Denka Seiken, Japan. The highest seropositivity rate and GMT values were found in the population group aged over 35 years coming into natural contact with the causative agent. Among the vaccinee population, the best outcomes were achieved in 2-9-year-olds (seropositivity rate: 94-100%, GMT: 2500-4000 EIA) and 10-14-year-olds (seropositivity rate: 93-97.1%, GMT almost 2000 EIA). The lowest seropositivity rate was found in the age group 20 to 24 years, more precisely in the 20-year-olds (78.4%), vaccinated with only one dose before the end of the first year of life. The seropositivity rates and GMT values vary with the vaccination strategies adopted in different years. The morbidity trend is supportive of the appropriateness of the vaccination strategy selected.
根据ESEN 2项目的要求，使用日本电気化学工业株式会社生产的商用麻疹IgG（II）酶免疫分析试剂盒，对来自捷克共和国1至64岁具有代表性人群样本的3013份血清进行了检测。在35岁以上自然接触病原体的人群组中发现了最高的血清阳性率和几何平均滴度（GMT）值。在接种疫苗的人群中，2至9岁儿童（血清阳性率：94 - 100%，GMT：2500 - 4000 EIA）和10至14岁儿童（血清阳性率：93 - 97.1%，GMT近2000 EIA）取得了最佳结果。在20至24岁年龄组中，血清阳性率最低，更确切地说是在1岁末之前仅接种一剂疫苗的20岁人群中（78.4%）。血清阳性率和GMT值因不同年份采用的疫苗接种策略而异。发病趋势支持所选疫苗接种策略的适宜性。
